Cover Image

Outcome of repeat dosing of sJIA patients with tocilizumab in one UK centre

Saved in:

Bibliographic Details
Main Authors:	Livermore P (Author), Woodworth T (Author), Woo P (Author)
Format:	Book
Published:	BMC, 2008-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
by: De Benedetti Fabrizio, et al.
Published: (2012)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data
by: Espada G, et al.
Published: (2011)

Application of the Yamaguchi criteria for classification of "suspected" systemic juvenile idiopathic arthritis (sJIA)
by: Kumar Sharath, et al.
Published: (2012)

Tocilizumab for the treatment of systemic onset JIA: a single centre experience from India
by: Sawhney Sujata, et al.
Published: (2012)

Experience of Vaccination of a Patient with Systemic Juvenile Idiopathic Arthritis (sJIA) with a 13-Valent Pneumococcal Conjugate Vaccine, prior to the Appointment of Therapy with Tocilizumab, an Anti-IL-6-Receptor Monoclonal Antibody
by: Daria D. Vankova, et al.
Published: (2018)

Severe sepsis caused by serious gastrointestinal infection in sJIA patients treated with IL-6 receptor antagonist: a case report
by: Meng Xu, et al.
Published: (2020)

An in-depth analysis of young people's experience of their juvenile idiopathic arthritis (JIA) once receiving Etanercept
by: Livermore P, et al.
Published: (2008)

The efficacy and safety of Tocilizumab in adults with refractory systemic onset JIA
by: Joly J, et al.
Published: (2011)

The 4th NextGen therapies for SJIA and MAS: part 2 phenotypes of refractory SJIA and the landscape for clinical trials in refractory SJIA
by: Grant Schulert, et al.
Published: (2024)

Experience of one UK site presenting a closer examination of safety and efficacy of Anakinra (Kineret<sup>®</sup>) in systemic juvenile idiopathic arthritis
by: Livermore P, et al.
Published: (2008)

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
by: Ruperto N, et al.
Published: (2008)

Tocilizumab in JIA patients who have inadequate response to anti-tumour necrosis factor therapy
by: Katsicas M, et al.
Published: (2011)

2.1 Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis (JIA)
by: Yokota S, et al.
Published: (2008)

Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study
by: Wael Hafez, et al.
Published: (2022)

Tocilizumab (TCZ) may be an effective treatment for poly-juvenile idiopathic arthritis (pJIA) as for rheumatoid arthritis (RA)
by: Yamaguchi Ken-ichi, et al.
Published: (2012)

The 4th NextGen therapies for SJIA and MAS: part 3 clinical trials in refractory SJIA: historic controls as an alternative to a withdrawal design study
by: Fabrizio de Benedetti, et al.
Published: (2024)

Jia Zhangke on Jia Zhangke
by: Berry, Michael
Published: (2022)

Jia Zhangke on Jia Zhangke
by: Berry, Michael
Published: (2022)

Tocilizumab (Actemra)
by: Martin Sheppard, et al.
Published: (2017)

DNase I levels and disease outcome in JIA patients treated with etanercept
by: Damjanov N, et al.
Published: (2011)

Juvenile idiopathic arthritis (JIA) in two tertiary centres in the Western Cape, South Africa
by: Pope Chris, et al.
Published: (2011)

Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes
by: Abeer Al-Baadani, et al.
Published: (2021)

Cone beam computed tomography in the assessment of TMJ deformity in children with JIA: repeatability of a novel scoring system
by: Thomas A. Augdal, et al.
Published: (2023)

Abatacept for severe anti-TNF-alfa refractory JIA-associated uveitis: one year follow-up
by: Traverso CE, et al.
Published: (2011)

Safety of Tocilizumab in COVID-19 Patients and Benefit of Single-Dose: The Largest Retrospective Observational Study
by: Ayman M. Al-Qaaneh, et al.
Published: (2022)

Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
by: Rania M. Sarhan, et al.
Published: (2022)

Overdose prevention centres in the UK
by: Adam Holland, et al.
Published: (2022)

'The current mental health status of children and young people with JIA, and their wider family': a charity partner collaboration survey
by: Polly Livermore, et al.
Published: (2023)

Efficacy of a second TNF blocker, when the first one failed, in patients with juvenile idiopathic arthritis (JIA)
by: Salmaso A, et al.
Published: (2008)

Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe
by: Alexei A. Grom, et al.
Published: (2024)

Development of the paediatric society of the African league against rheumatism (PAFLAR) JIA registry and clinical profile of JIA in Africa from the PAFLAR JIA registry
by: Angela Nyangore Migowa, et al.
Published: (2024)

Gene expression in active systemic JIA after anti-IL1 and anti-IL6R treatment
by: Ogilvie EM, et al.
Published: (2008)

Investigating the use of a limited core outcome variable set for the classification of response following methotrexate treatment in juvenile idiopathic arthritis (JIA)
by: Hirani SP, et al.
Published: (2008)

Trajectories of disease courses in the inception cohort of newly diagnosed patients with JIA (ICON-JIA): the potential of serum biomarkers at baseline
by: Margarita Ganeva, et al.
Published: (2021)

Proceedings from the 4th NextGen Therapies for SJIA and MAS virtual symposium held February 13-14, 2022
by: Rashmi Sinha, et al.
Published: (2024)

MEFV mutations in systemic JIA
by: Aktay Ayaz N, et al.
Published: (2008)

Tocilizumab prescribing criteria for COVID-19 patients
by: Ayman M. Al-Qaaneh, et al.
Published: (2021)

Mesenchymal stem cells and JIA
by: Slaper-Cortenbach I, et al.
Published: (2011)

Tocilizumab in the treatment of rheumatoid arthritis and beyond
by: Shetty A, et al.
Published: (2014)

Investigating which variables from the core outcome variables in juvenile idiopathic arthritis (JIA) are the best predictors of classification as a responder to treatment with methotrexate (MTX)
by: Hirani SP, et al.
Published: (2008)